Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
1,856 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Comparative efficacy and safety of biologics and systemic immunomodulatory treatments for chronic urticaria: Systematic review and network meta-analysis.
Chu AWL, Oykhman P, Chu X, et al. · J Allergy Clin Immunol · 2025Comparative Study, Network Meta-Analysis
- Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials.
Maurer M, Casale TB, Saini SS, et al. · J Allergy Clin Immunol · 2024Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and Safety of Systemic Corticosteroids for Urticaria: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Chu X, Wang J, Ologundudu L, et al. · J Allergy Clin Immunol Pract · 2024Systematic Review, Meta-Analysis
- Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis.
Fricke J, Ávila G, Keller T, et al. · Allergy · 2020Meta-Analysis, Systematic Review
- Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis.
Guillén-Aguinaga S, Jáuregui Presa I, Aguinaga-Ontoso E, et al. · Br J Dermatol · 2016Comparative Study, Meta-Analysis
- Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies.
Giménez-Arnau AM, Szalewski R, Hide M, et al. · J Allergy Clin Immunol · 2026Randomized Controlled Trial, Clinical Trial, Phase III
- Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
Maurer M, Rosén K, Hsieh HJ, et al. · N Engl J Med · 2013Clinical Trial, Phase III, Multicenter Study
- Omalizumab in pediatric chronic spontaneous urticaria: A systematic review and meta-analysis of efficacy and safety.
Alomari O, Ozceker D, Mokresh ME, et al. · Pediatr Allergy Immunol · 2025Systematic Review, Meta-Analysis
- Anti-KIT Barzolvolimab for Chronic Spontaneous Urticaria.
Maurer M, Metz M, Anderson J, et al. · Allergy · 2025Randomized Controlled Trial, Clinical Trial, Phase I
- Efficacy, Safety, and Quality-of-Life Outcomes of Remibrutinib in Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis.
Khan AA, Riaz AA, Naseer F, et al. · J Allergy Clin Immunol Pract · 2025Systematic Review, Meta-Analysis
- Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria.
Maurer M, Berger W, Giménez-Arnau A, et al. · J Allergy Clin Immunol · 2022Randomized Controlled Trial
- Topical corticosteroids for hives and itch (urticaria): Systematic review and Bayesian meta-analysis of randomized trials.
Chu AWL, Rayner DG, Chu X, et al. · Ann Allergy Asthma Immunol · 2024Systematic Review, Meta-Analysis
- Efficacy of Acupuncture for Chronic Spontaneous Urticaria : A Randomized Controlled Trial.
Zheng H, Xiao XJ, Shi YZ, et al. · Ann Intern Med · 2023Randomized Controlled Trial, Multicenter Study
- Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.
Saini SS, Bindslev-Jensen C, Maurer M, et al. · J Invest Dermatol · 2015Clinical Trial, Phase III, Multicenter Study
- Dupilumab in Patients With Chronic Spontaneous Urticaria: Phase 3 LIBERTY-CSU CUPID Randomized Clinical Trials.
Casale TB, Saini SS, Ben-Shoshan M, et al. · JAMA Dermatol · 2026Clinical Trial, Phase III, Randomized Controlled Trial
- Omalizumab for treatment of idiopathic angioedema.
Goswamy VP, Lee KE, McKernan EM, et al. · Ann Allergy Asthma Immunol · 2022Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Comparative Safety Profiles of Individual Second-Generation H1-Antihistamines for the Treatment of Chronic Urticaria: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Chaichan W, Ruengorn C, Thavorn K, et al. · J Allergy Clin Immunol Pract · 2023Systematic Review, Research Support, Non-U.S. Gov't
- Comparative Effectiveness and Safety of Second-Generation Antihistamines Treatments for Chronic Urticaria: A Network Meta-Analysis.
Tian HY, Xu C, Liu CJ, et al. · Int Arch Allergy Immunol · 2026Network Meta-Analysis, Comparative Study
- Leukotriene receptor antagonists as add-on therapy to antihistamines for urticaria: Systematic review and meta-analysis of randomized clinical trials.
Rayner DG, Liu M, Chu AWL, et al. · J Allergy Clin Immunol · 2024Systematic Review, Meta-Analysis
- Efficacy and safety of bilastine vs. levocetirizine for the treatment of chronic idiopathic urticaria: A multicenter, double-blind, double-dummy, phase III, non-inferiority, randomized clinical trial.
Chen X, Han X, Cheng B, et al. · Chin Med J (Engl) · 2024Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Maurer M, Ensina LF, Gimenez-Arnau AM, et al. · Lancet · 2024Clinical Trial, Phase III, Randomized Controlled Trial
- Ligelizumab for Chronic Spontaneous Urticaria.
Maurer M, Giménez-Arnau AM, Sussman G, et al. · N Engl J Med · 2019Clinical Trial, Phase II, Comparative Study
- Randomized dose-finding study of anti-KIT barzolvolimab in patients with chronic spontaneous urticaria.
Metz M, Mitha E, Leflein J, et al. · J Allergy Clin Immunol · 2026Randomized Controlled Trial, Clinical Trial, Phase II
- Systematic review and meta-analysis: Effect of Helicobacter pylori eradication on chronic spontaneous urticaria.
Kim HJ, Kim YJ, Lee HJ, et al. · Helicobacter · 2019Meta-Analysis, Systematic Review
- Cyclosporine for Chronic Spontaneous Urticaria: A Meta-Analysis and Systematic Review.
Kulthanan K, Chaweekulrat P, Komoltri C, et al. · J Allergy Clin Immunol Pract · 2018Meta-Analysis, Systematic Review
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.